An antiparkinsonian agent. A non-ergoline selective agonist of dopamine D2 and D3 receptors. A possible mechanism of action in the treatment of Parkinson's disease , associated with a stimulating effect on the postsynaptic D2 receptors of the basal nuclei in the brain.
Your order will be packed safe and secure and dispatched within 24 hours. This is exactly how your parcel will look like (pictures of a real shipping item). It has a size and a look of a regular private letter (9.4x4.3x0.3 inches or 24x11x0.7cm) and it does not disclose its contents
Requip Product Description
Requip is a non-ergoline dopamine agonist, stimulating striatal dopamine receptors and improving the chemical imbalance in the brain affected by Parkinson's disease. This drug provides an effect in the hypothalamus and pituitary by inhibiting the prolactin secretion.
Requip is indicated to adults for treatment of Parkinson's disease symptoms as monotherapy or in combination with levodopa. The application of the antiparkinson drug can delay administration of levodopa.
In addition, Requip may also be administered for treatment of moderate-to-severe primary restless legs syndrome. This neurological disorder is characterized by unpleasant sensations in the legs, often appearing during the night.
An initial recommended dose of Requip is 0.75 mg per day (one 0.25 mg tablet of Requip three times a day) for 7 days. Then the daily dose is to be increased, taking into account the tolerance to the antiparkinson drug and the therapeutic response. The maximum Requip dose should not exceed 24 mg per day.
If the patient had missed the dose of Requip, s/he must skip the tablet in case if it is close to the next scheduled dose of this antiparkinsonian agent. If it is enough time till the next dose of Requip, the patient can use a tablet immediately as it possible.
When Requip is prescribed as an adjunct to levodopa therapy, the daily dose of levodopa is recommended to be reduced. This will help avoid excessive dopamine stimulation and development of side effects. Levodopa dosage should be decreased gradually.
Recommended temperature for Requip storage is from 20°C to 25°C. Keep the tablets in a warm dry place in a tightly closed bottle.
Requip Safety Information
Requip may cause sudden sleep attacks and daytime sleepiness. The patients feeling sleepy should be advised not to drive a motor vehicle or operate machinery. In order to reduce the risk of sudden sleep attacks, the daily dose of the antiparkinson drug should be decreased. If cases of sudden onset of sleep are failed to be minimized, it is recommended to stop taking Requip and to consider alternative treatments for Parkinson's disease.
All the information about Parkinson's Disease, which is included in the review of Requip, is published for general information purpose only, and should not be taken as a substitute for professional advice of the qualified medical professional. The online pharmacy shall disclaim any responsibility for any kind of consequences, including damage or loss, which may follow from the use of information about antiparkinsonian agent, Requip.
Requip Side Effects
The most common adverse events, caused by Requip, include vomiting, heartburn, nausea, syncope, dizziness, abdominal pain, dyskinesia. They usually appear at the beginning of the treatment with the antiparkinsonian agent, are mild, and rarely result in withdrawal of Requip. Less commonly, the antiparkinsonian drug may cause other adverse events, such as leg edema, sweating, confusion, dyspepsia, hallucinations, viral infection, somnolence, headache or asthenic condition. The intensity and frequency of Requip adverse events can be reduced by lowering the dose.